Rituximab in the management of refractory myasthenia gravis

Nazlee Zebardast, Huned S. Patwa, Steven P. Novella, Jonathan M. Goldstein

Research output: Contribution to journalArticlepeer-review

80 Scopus citations


Myasthenia gravis (MG) is an immune-mediated disorder with a variable response to treatment. In this study, patients with refractory MG who were treated with rituximab were identified. A review of patients referred to the Yale Neuromuscular Clinic was performed. Patients with refractory MG who were treated with rituximab were reviewed for response to treatment. Patients who had muscle-specific kinase (MuSK+) or acetylcholine receptor (AChR +) antibodies were included. Six patients were identified who met the criteria described. All patients tolerated rituximab without side effects and had a reduced need for immunosuppressants and/or improvement in clinical function. Patients with refractory MG appeared to respond to rituximab in this small, retrospective study. This result suggests that a larger, prospective trial is indicated.

Original languageEnglish (US)
Pages (from-to)375-378
Number of pages4
JournalMuscle and Nerve
Issue number3
StatePublished - Mar 1 2010


  • Immunosuppression
  • Myasthenia gravis
  • Refractory
  • Rituximab
  • Treatment

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)


Dive into the research topics of 'Rituximab in the management of refractory myasthenia gravis'. Together they form a unique fingerprint.

Cite this